TANK-binding kinase 1 (TBK1) modulates inflammatory hyperalgesia by regulating MAP kinases and NF-κB dependent genes

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Möser, Christine V ^a   Stephan, Heike ^a   Altenrath, Katharina ^a   Kynast, Katharina L ^a   Russe, Otto Q ^a   Olbrich, Katrin ^a   Geisslinger, Gerd ^a   Niederberger, Ellen ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

c fos; I B Kinases; Inflammation; Nociception; TBK1

Indexed keywords

CYCLOOXYGENASE 2; ENZYME ANTIBODY; GELATINASE B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C FOS; TANK BINDING KINASE 1; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CCDC88A PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN SERINE THREONINE KINASE; PTGS2 PROTEIN, MOUSE; TBK1 PROTEIN, MOUSE;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; COX 2 GENE; EMBRYO; ENZYME LOCALIZATION; ENZYME REGULATION; FORMALIN TEST; GENE; GENE DELETION; GENE INACTIVATION; GENETIC REGULATION; HOT PLATE TEST; HYPERALGESIA; INFLAMMATORY PAIN; INOS GENE; MECHANICAL HYPERALGESIA; MMP 9 GENE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NOCICEPTION; NONHUMAN; PROTEIN EXPRESSION; ROTAROD TEST; SIGNAL TRANSDUCTION; TBK1 GENE; ANIMAL; C57BL MOUSE; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; MOTOR ACTIVITY; PAIN THRESHOLD; PATHOLOGY; PHYSIOLOGY; SPINAL CORD; SPINAL GANGLION; TIME FACTOR; TRANSFORMED CELL LINE; TRANSGENIC MOUSE;

ANIMALS; CELL LINE, TRANSFORMED; CYCLOOXYGENASE 2; GANGLIA, SPINAL; GENE EXPRESSION REGULATION; HYPERALGESIA; INFLAMMATION; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOTOR ACTIVITY; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PAIN THRESHOLD; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-FOS; SPINAL CORD; TIME FACTORS;

EID: 84930654717     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0319-3     Document Type: Article

References (43)

1. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003;4:491-6.
2. Peters RT, Liao SM, Maniatis T. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell. 2000;5:513-22.
3. Shimada T, Kawai T, Takeda K, Matsumoto M, Inoue J, Tatsumi Y, et al. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol. 1999;11:1357-62.
4. Pomerantz JL, Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. Embo J. 1999;18:6694-704.
5. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science. 2007;315:1274-8.
6. Ng SL, Friedman BA, Schmid S, Gertz J, Myers RM, Tenoever BR, et al. IkappaB kinase epsilon (IKK(epsilon)) regulates the balance between type I and type II interferon responses. Proc Natl Acad Sci U S A. 2011;108:21170-5.
7. Niederberger E, Moser C, Kynast K, Geisslinger G: The non-canonical IkappaB kinases IKKepsilon and TBK1 as potential targets for the development of novel therapeutic drugs. Curr Mol Med 2013,;13(7):1089-97
8. Niederberger E, Geisslinger G. The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy? Faseb J. 2008;22:3432-42.
9. Niederberger E, Schmidtko A, Gao W, Kuhlein H, Ehnert C, Geisslinger G. Impaired acute and inflammatory nociception in mice lacking the p50 subunit of NF-kappaB. Eur J Pharmacol. 2007;559:55-60.
10. Tegeder I, Niederberger E, Schmidt R, Kunz S, Guhring H, Ritzeler O, et al. Specific inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci. 2004;24:1637-45.
11. Ebersberger A, Buchmann M, Ritzeler O, Michaelis M, Schaible HG. The role of spinal nuclear factor-kappa B in spinal hyperexcitability. Neuroreport. 2006;17:1615-8.
12. Bockhart V, Constantin CE, Haussler A, Wijnvoord N, Kanngiesser M, Myrczek T, et al. Inhibitor kappaB Kinase beta deficiency in primary nociceptive neurons increases TRP channel sensitivity. J Neurosci. 2009;29:12919-29.
13. Moser CV, Kynast K, Baatz K, Russe OQ, Ferreiros N, Costiuk H, et al. The protein kinase IKKepsilon is a potential target for the treatment of inflammatory hyperalgesia. J Immunol. 2011;187:2617-25.
14. Lee JK, Kim SY, Kim YS, Lee WH, Hwang DH, Lee JY. Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin. Biochem Pharmacol. 2009;77:1391-400.
15. Xie XH, Zang N, Li SM, Wang LJ, Deng Y, He Y, et al. Resveratrol inhibits respiratory syncytial virus-induced IL-6 production, decreases viral replication, and downregulates TRIF expression in airway epithelial cells. Inflammation. 2012;35:1392-401.
16. Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med. 2004;199:1641-50.
17. Hammaker D, Boyle DL, Firestein GS: Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis. Rheumatology (Oxford) 2012,;51(4):610-8
18. Munoz MC, Giani JF, Mayer MA, Toblli JE, Turyn D, Dominici FP. TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance. J Endocrinol. 2009;201:185-97.
19. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73:457-67.
20. Perry AK, Chow EK, Goodnough JB, Yeh WC, Cheng G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med. 2004;199:1651-8.
21. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, et al. Heritability of nociception II. 'Types' of nociception revealed by genetic correlation analysis. Pain. 1999;80:83-93.
22. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 1977;4:161-74.
23. Meller ST, Gebhart GF. Intraplantar zymosan as a reliable, quantifiable model of thermal and mechanical hyperalgesia in the rat. Eur J Pain. 1997;1:43-52.
24. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain. 1987;30:103-14.
25. Kominato Y, Tachibana T, Dai Y, Tsujino H, Maruo S, Noguchi K. Changes in phosphorylation of ERK and Fos expression in dorsal horn neurons following noxious stimulation in a rat model of neuritis of the nerve root. Brain Res. 2003;967:89-97.
26. Sgambato V, Pages C, Rogard M, Besson MJ, Caboche J. Extracellular signal-regulated kinase (ERK) controls immediate early gene induction on corticostriatal stimulation. J Neurosci. 1998;18:8814-25.
27. Coste O, Moser CV, Sisignano M, Kynast KL, Minden A, Geisslinger G, et al. The p21-activated kinase PAK 5 is involved in formalin-induced nociception through regulation of MAP-kinase signaling and formalin-specific receptors. Behav Brain Res. 2012;234:121-8.
28. Russe OQ, Moser CV, Kynast KL, King TS, Stephan H, Geisslinger G, et al. Activation of the AMP-activated protein kinase reduces inflammatory nociception. J Pain. 2013;14:1330-40.
29. Ji RR, Gereau RW, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev. 2009;60:135-48.
30. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17-26.
31. Kanngiesser M, Haussler A, Myrczek T, Kusener N, Lim HY, Geisslinger G, et al. Inhibitor kappa B kinase beta dependent cytokine upregulation in nociceptive neurons contributes to nociceptive hypersensitivity after sciatic nerve injury. J Pain. 2012;13:485-97.
32. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007;13:460-9.
33. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;2006:re13.
34. Bonnard M, Mirtsos C, Suzuki S, Graham K, Huang J, Ng M, et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. Embo J. 2000;19:4976-85.
35. Geis C, Graulich M, Wissmann A, Hagenacker T, Thomale J, Sommer C, et al. Evoked pain behavior and spinal glia activation is dependent on tumor necrosis factor receptor 1 and 2 in a mouse model of bone cancer pain. Neuroscience. 2010;169:463-74.
36. Zhang L, Berta T, Xu ZZ, Liu T, Park JY, Ji RR. TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain. 2011;152:419-27.
37. Vogel C, Stallforth S, Sommer C. Altered pain behavior and regeneration after nerve injury in TNF receptor deficient mice. J Peripher Nerv Syst. 2006;11:294-303.
38. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, et al. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013;19:313-21.
39. Mowers J, Uhm M, Reilly SM, Simon J, Leto D, Chiang SH, et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKK{varepsilon} and TBK1. Elife. 2013;2, e01119.
40. Delhase M, Kim SY, Lee H, Naiki-Ito A, Chen Y, Ahn ER, et al. TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proc Natl Acad Sci U S A. 2012;109:E177-86.
41. Abe T, Barber GN. Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF-kappaB Activation through TBK1. J Virol. 2014;88:5328-41.
42. Bruni D, Sebastia J, Dunne S, Schroder M, Butler MP. A novel IRAK1-IKKepsilon signaling axis limits the activation of TAK1-IKKbeta downstream of TLR3. J Immunol. 2013;190:2844-56.
43. Tu YC, Huang DY, Shiah SG, Wang JS, Lin WW. Regulation of c-Fos gene expression by NF-kappaB: a p65 homodimer binding site in mouse embryonic fibroblasts but not human HEK293 cells. PLoS One. 2013;8, e84062.